Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2025 | 1005 | 2.480 |
Why?
|
| Neoplasms | 11 | 2026 | 457 | 2.300 |
Why?
|
| Formaldehyde | 3 | 2026 | 6 | 1.740 |
Why?
|
| Epigenomics | 2 | 2025 | 6 | 1.560 |
Why?
|
| Biomarkers, Tumor | 4 | 2026 | 148 | 1.480 |
Why?
|
| Survivors | 6 | 2016 | 157 | 1.450 |
Why?
|
| Continuity of Patient Care | 6 | 2020 | 95 | 1.430 |
Why?
|
| Cancer Survivors | 6 | 2025 | 115 | 1.430 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2023 | 540 | 1.430 |
Why?
|
| DNA | 3 | 2026 | 26 | 1.400 |
Why?
|
| Medical Oncology | 6 | 2023 | 33 | 1.240 |
Why?
|
| Papillomavirus Infections | 4 | 2025 | 144 | 1.200 |
Why?
|
| Museums | 4 | 2026 | 4 | 1.150 |
Why?
|
| Diagnostic Imaging | 3 | 2018 | 42 | 1.070 |
Why?
|
| Humans | 45 | 2026 | 17622 | 1.030 |
Why?
|
| Specimen Handling | 2 | 2026 | 25 | 1.010 |
Why?
|
| Preservation, Biological | 1 | 2026 | 1 | 0.970 |
Why?
|
| Depression | 3 | 2023 | 507 | 0.960 |
Why?
|
| Mass Screening | 6 | 2025 | 693 | 0.950 |
Why?
|
| Colorectal Neoplasms | 5 | 2024 | 642 | 0.950 |
Why?
|
| Gene Expression Regulation | 1 | 2025 | 23 | 0.930 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 26 | 0.920 |
Why?
|
| Female | 31 | 2026 | 12715 | 0.910 |
Why?
|
| Tissue Fixation | 1 | 2024 | 3 | 0.860 |
Why?
|
| Chromatin | 1 | 2024 | 6 | 0.860 |
Why?
|
| Genome, Mitochondrial | 1 | 2024 | 2 | 0.830 |
Why?
|
| Early Detection of Cancer | 7 | 2025 | 559 | 0.820 |
Why?
|
| Animals | 6 | 2026 | 285 | 0.820 |
Why?
|
| Guideline Adherence | 4 | 2026 | 155 | 0.820 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2016 | 308 | 0.780 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2025 | 135 | 0.700 |
Why?
|
| California | 13 | 2026 | 2433 | 0.680 |
Why?
|
| Community Health Services | 1 | 2022 | 78 | 0.680 |
Why?
|
| Referral and Consultation | 2 | 2022 | 161 | 0.680 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 114 | 0.670 |
Why?
|
| Medical Overuse | 2 | 2018 | 14 | 0.670 |
Why?
|
| Middle Aged | 19 | 2026 | 7954 | 0.650 |
Why?
|
| Patient Portals | 1 | 2021 | 23 | 0.650 |
Why?
|
| Adult | 19 | 2026 | 7621 | 0.630 |
Why?
|
| Population Surveillance | 3 | 2016 | 248 | 0.620 |
Why?
|
| Male | 18 | 2026 | 10014 | 0.590 |
Why?
|
| Practice Guidelines as Topic | 4 | 2026 | 319 | 0.560 |
Why?
|
| Neoplasm Staging | 6 | 2023 | 350 | 0.520 |
Why?
|
| Patient Care | 3 | 2026 | 30 | 0.520 |
Why?
|
| Young Adult | 10 | 2026 | 2538 | 0.510 |
Why?
|
| Aged | 16 | 2026 | 6223 | 0.480 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 278 | 0.470 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 21 | 0.470 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 54 | 0.460 |
Why?
|
| Perception | 2 | 2024 | 56 | 0.440 |
Why?
|
| Retrospective Studies | 10 | 2026 | 2502 | 0.430 |
Why?
|
| Patient Care Planning | 3 | 2016 | 45 | 0.430 |
Why?
|
| Surveys and Questionnaires | 7 | 2026 | 1296 | 0.420 |
Why?
|
| Quality of Health Care | 4 | 2018 | 260 | 0.400 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 73 | 0.400 |
Why?
|
| Social Support | 2 | 2016 | 215 | 0.400 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 403 | 0.400 |
Why?
|
| Colonic Neoplasms | 2 | 2025 | 164 | 0.390 |
Why?
|
| Health Status Disparities | 2 | 2025 | 151 | 0.380 |
Why?
|
| Adolescent | 8 | 2026 | 3625 | 0.380 |
Why?
|
| Health Services Research | 3 | 2019 | 201 | 0.370 |
Why?
|
| Rehabilitation | 1 | 2012 | 2 | 0.360 |
Why?
|
| Physicians | 1 | 2013 | 120 | 0.350 |
Why?
|
| Incidence | 5 | 2026 | 1278 | 0.340 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 383 | 0.320 |
Why?
|
| Electronic Health Records | 6 | 2025 | 719 | 0.310 |
Why?
|
| Quality of Life | 3 | 2026 | 505 | 0.300 |
Why?
|
| Aftercare | 3 | 2020 | 47 | 0.300 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 208 | 0.290 |
Why?
|
| Oncology Nursing | 1 | 2008 | 2 | 0.280 |
Why?
|
| Registries | 5 | 2026 | 475 | 0.270 |
Why?
|
| Documentation | 1 | 2008 | 38 | 0.270 |
Why?
|
| Patient Care Management | 1 | 2008 | 24 | 0.270 |
Why?
|
| Phylogeny | 2 | 2026 | 19 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 120 | 0.270 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 1976 | 0.260 |
Why?
|
| Chiroptera | 1 | 2026 | 1 | 0.240 |
Why?
|
| Metagenomics | 1 | 2026 | 1 | 0.240 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2026 | 1 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2026 | 248 | 0.240 |
Why?
|
| Rotavirus | 1 | 2026 | 17 | 0.240 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2026 | 3 | 0.240 |
Why?
|
| Parthenogenesis | 1 | 2026 | 1 | 0.240 |
Why?
|
| Triploidy | 1 | 2026 | 1 | 0.240 |
Why?
|
| Hodgkin Disease | 1 | 2025 | 4 | 0.240 |
Why?
|
| Thyroid Neoplasms | 1 | 2025 | 15 | 0.230 |
Why?
|
| Gene-Environment Interaction | 1 | 2025 | 21 | 0.230 |
Why?
|
| Erythrocytes | 1 | 2025 | 8 | 0.230 |
Why?
|
| Genetic Variation | 1 | 2026 | 82 | 0.230 |
Why?
|
| Positron-Emission Tomography | 2 | 2015 | 32 | 0.230 |
Why?
|
| Trastuzumab | 1 | 2025 | 19 | 0.230 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 10 | 0.230 |
Why?
|
| Health Promotion | 1 | 2008 | 293 | 0.230 |
Why?
|
| Psychometrics | 1 | 2026 | 119 | 0.230 |
Why?
|
| DNA Methylation | 1 | 2025 | 45 | 0.220 |
Why?
|
| Patient Education as Topic | 2 | 2022 | 193 | 0.220 |
Why?
|
| Community Networks | 2 | 2016 | 21 | 0.220 |
Why?
|
| Fixatives | 1 | 2024 | 1 | 0.220 |
Why?
|
| Vertebrates | 1 | 2024 | 1 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 60 | 0.220 |
Why?
|
| Medical Records | 2 | 2015 | 91 | 0.210 |
Why?
|
| Mammography | 2 | 2015 | 173 | 0.210 |
Why?
|
| Qualitative Research | 2 | 2023 | 290 | 0.210 |
Why?
|
| Health Priorities | 2 | 2020 | 24 | 0.210 |
Why?
|
| Sequence Analysis, DNA | 1 | 2024 | 32 | 0.210 |
Why?
|
| Algorithms | 1 | 2025 | 227 | 0.200 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 2 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 368 | 0.200 |
Why?
|
| Occult Blood | 2 | 2024 | 162 | 0.200 |
Why?
|
| Pandemics | 2 | 2022 | 295 | 0.200 |
Why?
|
| Chronic Disease | 1 | 2025 | 398 | 0.190 |
Why?
|
| Rectal Neoplasms | 1 | 2023 | 75 | 0.190 |
Why?
|
| Child | 3 | 2022 | 2485 | 0.190 |
Why?
|
| Time Factors | 4 | 2023 | 1038 | 0.190 |
Why?
|
| Risk Factors | 5 | 2025 | 3291 | 0.180 |
Why?
|
| Social Class | 1 | 2022 | 117 | 0.180 |
Why?
|
| Laboratories | 1 | 2022 | 19 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 380 | 0.180 |
Why?
|
| Hyperkalemia | 1 | 2022 | 15 | 0.180 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 46 | 0.170 |
Why?
|
| Medical Informatics | 1 | 2021 | 33 | 0.170 |
Why?
|
| Hip Fractures | 1 | 2022 | 74 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 53 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 84 | 0.170 |
Why?
|
| Quarantine | 1 | 2021 | 10 | 0.170 |
Why?
|
| Quality Improvement | 3 | 2019 | 189 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 109 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2020 | 9 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 1 | 2022 | 124 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2020 | 77 | 0.160 |
Why?
|
| United States | 5 | 2020 | 3922 | 0.160 |
Why?
|
| Hypertension | 1 | 2025 | 486 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2020 | 31 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 158 | 0.140 |
Why?
|
| Prevalence | 2 | 2024 | 830 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 10 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 187 | 0.130 |
Why?
|
| Vaccination | 1 | 2022 | 726 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 56 | 0.130 |
Why?
|
| Oncologists | 1 | 2016 | 7 | 0.130 |
Why?
|
| Culture | 1 | 2016 | 30 | 0.130 |
Why?
|
| Pneumonectomy | 1 | 2016 | 6 | 0.120 |
Why?
|
| Learning | 1 | 2016 | 18 | 0.120 |
Why?
|
| Sinusitis | 1 | 2016 | 18 | 0.120 |
Why?
|
| Patient Selection | 1 | 2017 | 181 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 214 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 27 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 10 | 0.120 |
Why?
|
| Mid-Atlantic Region | 1 | 2015 | 6 | 0.120 |
Why?
|
| Sampling Studies | 1 | 2015 | 43 | 0.120 |
Why?
|
| Utah | 2 | 2025 | 38 | 0.120 |
Why?
|
| Northwestern United States | 1 | 2015 | 53 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 50 | 0.120 |
Why?
|
| Office Visits | 1 | 2016 | 75 | 0.120 |
Why?
|
| Anxiety | 1 | 2016 | 162 | 0.110 |
Why?
|
| Papillomaviridae | 2 | 2025 | 61 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 152 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2025 | 87 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 215 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 346 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2015 | 631 | 0.100 |
Why?
|
| Linear Models | 1 | 2014 | 204 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2013 | 14 | 0.100 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 88 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 527 | 0.100 |
Why?
|
| Minority Groups | 2 | 2023 | 104 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2013 | 107 | 0.090 |
Why?
|
| Primary Health Care | 2 | 2016 | 729 | 0.090 |
Why?
|
| Health Care Costs | 2 | 2025 | 211 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2016 | 2502 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2025 | 545 | 0.080 |
Why?
|
| Nursing Research | 1 | 2008 | 2 | 0.070 |
Why?
|
| Models, Nursing | 1 | 2008 | 3 | 0.070 |
Why?
|
| National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division | 1 | 2008 | 4 | 0.070 |
Why?
|
| Information Services | 1 | 2008 | 12 | 0.070 |
Why?
|
| Nurse's Role | 1 | 2008 | 7 | 0.070 |
Why?
|
| Total Quality Management | 1 | 2008 | 18 | 0.070 |
Why?
|
| Comprehensive Health Care | 1 | 2008 | 8 | 0.070 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 190 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 25 | 0.070 |
Why?
|
| Health Policy | 1 | 2008 | 106 | 0.070 |
Why?
|
| Counseling | 1 | 2008 | 173 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2026 | 48 | 0.060 |
Why?
|
| Karyotype | 1 | 2026 | 1 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2026 | 9 | 0.060 |
Why?
|
| Australia | 1 | 2026 | 26 | 0.060 |
Why?
|
| Heterozygote | 1 | 2026 | 30 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2026 | 35 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2025 | 41 | 0.060 |
Why?
|
| Genotype | 1 | 2026 | 224 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2025 | 51 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2025 | 90 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2025 | 85 | 0.060 |
Why?
|
| Physicians, Primary Care | 1 | 2026 | 63 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2026 | 363 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2025 | 237 | 0.050 |
Why?
|
| Papanicolaou Test | 1 | 2024 | 38 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2024 | 48 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2026 | 369 | 0.050 |
Why?
|
| Medicaid | 1 | 2024 | 188 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 65 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2024 | 265 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 323 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 12 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 41 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 30 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 35 | 0.040 |
Why?
|
| Government Programs | 1 | 2020 | 11 | 0.040 |
Why?
|
| Research Personnel | 1 | 2020 | 28 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 266 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 686 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 446 | 0.030 |
Why?
|
| Income | 1 | 2017 | 86 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 197 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 19 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1157 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 79 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 144 | 0.030 |
Why?
|
| Health Education | 1 | 2016 | 82 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 609 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 552 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 193 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 204 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 337 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2016 | 1161 | 0.020 |
Why?
|
Concepts
(225)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->